Siga Technologies Intrinsic Value – Edison Inv. Res Predicts Robust FY2024 Earnings for SIGA Technologies,
March 25, 2023
Trending News ☀️
Edison Inv. Res has announced their expectations for SIGA ($NASDAQ:SIGA) Technologies, Inc.’s financial performance for the fiscal year 2024. According to their estimates, SIGA Technologies, Inc. stands to have a robust year with earnings far exceeding previous years. The analysts expect the company’s growth to be driven by the success of its innovative products and services, as well as its ever-expanding customer base. The projection is an encouraging one, particularly in light of the disruption caused by the pandemic.
SIGA Technologies, Inc. has managed to pivot its operations to take advantage of the new opportunities available, and this is expected to pay off in the form of improved earnings. The analysts also believe that SIGA Technologies, Inc.’s dedicated focus on delivering high-quality, reliable services and products is likely to contribute significantly to their success. Res is confident that SIGA Technologies, Inc.’s success in FY2024 will be remarkable, and that their performance could be a major contributor to their long-term sustainability and growth. With their robust portfolio and strategic direction, the company looks set for success in the year ahead.
Stock Price
On Friday, Edison Investment Research released an optimistic forecast of SIGA Technologies, Inc.’s FY2024 earnings, predicting that the cyber security solutions provider will have a robust year. This prediction has been met with mostly positive media coverage, as investors and analysts alike anticipate strong results from the company. Despite this news, SIGA TECHNOLOGIES stock opened at $5.6 on Friday and closed at $5.5, down by 2.8% from its previous closing price of $5.6. The reasons for this decline remain unclear, but investors will keep a close eye on the company’s performance in the coming months to see if Edison’s prediction of strong FY2024 earnings will be met. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Siga Technologies. More…
| Total Revenues | Net Income | Net Margin |
| 110.78 | 33.9 | 30.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Siga Technologies. More…
| Operations | Investing | Financing |
| 41.61 | 0 | -45.96 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Siga Technologies. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 195.04 | 24.88 | 2.34 |
Key Ratios Snapshot
Some of the financial key ratios for Siga Technologies are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 60.6% | -36.9% | 39.8% |
| FCF Margin | ROE | ROA |
| 37.6% | 16.1% | 14.1% |
Analysis – Siga Technologies Intrinsic Value
At GoodWhale, we have conducted an analysis of SIGA TECHNOLOGIES’s wellbeing. Using our proprietary Valuation Line, we have calculated the fair value of SIGA TECHNOLOGIES’s stock to be around $8.0. However, currently the stock is trading at $5.5, meaning it is undervalued by 30.8%. This presents investors with an opportunity to purchase shares at a discounted rate. We recommend investors take advantage of this opportunity and invest in SIGA TECHNOLOGIES soon. More…
Peers
The company’s lead product, Tpoxx, is currently in Phase III clinical trials. SIGA Technologies Inc’s main competitors are Tonix Pharmaceuticals Holding Corp, Chimerix Inc, and Emergent BioSolutions Inc.
– Tonix Pharmaceuticals Holding Corp ($NASDAQ:TNXP)
The company’s market cap is 25.14M as of 2022 and has a ROE of -26.13%. The company focuses on the development and commercialization of pharmaceutical products for the treatment of chronic pain and other disorders.
– Chimerix Inc ($NASDAQ:CMRX)
Chimerix Inc is a pharmaceutical company that focuses on developing antiviral therapies. The company’s market cap as of 2022 is 155.09M. The company’s ROE is -175.55%. The company’s focus on developing antiviral therapies makes it a unique player in the pharmaceutical industry. The company’s products are in development for the treatment of various viral infections, including HIV, hepatitis C, and influenza. The company’s products are also being evaluated for the treatment of cancer.
– Emergent BioSolutions Inc ($NYSE:EBS)
Emergent BioSolutions Inc. is a global biopharmaceutical company that develops, manufactures, and markets vaccines and therapeutics for infectious diseases and autoimmune disorders. The company’s products include anthrax, smallpox, and botulism vaccines; and treatments for autoimmune and inflammatory diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis. It also offers contract manufacturing and development services to government and commercial customers.
Summary
SIGA Technologies, Inc. is garnering investor interest and is predicted to post robust earnings results for FY 2024, according to a recent report from Edison Investment Research. Analysts are expecting revenue growth and earnings growth to exceed that of the industry average, driven by potential new product rollouts and cost-cutting measures. Moreover, SIGA has a strong balance sheet and its portfolio of products is expected to remain resilient in uncertain economic times. Despite the pandemic, SIGA’s prospects remain bright and investors are keeping a close eye on this technology company.
